Research ExplorerPublicationsLong-term outcome after allogeneic hematopoietic cell transp...

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis

Standard

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis. / Robin, Marie; de Wreede, Liesbeth C; Wolschke, Christine; Schetelig, Johannes; Eikema, Dirk-Jan; Van Lint, Maria Teresa; Knelange, Nina Simone; Beelen, Dietrich; Brecht, Arne; Niederwieser, Dietger; Vitek, Antonin; Bethge, Wolfgang; Arnold, Renate; Finke, Jürgen; Volin, Liisa; Yakoub-Agha, Ibrahim; Nagler, Arnon; Poiré, Xavier; Einsele, Hermann; Chevallier, Patrice; Holler, Ernst; Ljungman, Per; Robinson, Stephen; Radujkovic, Aleksandar; McLornan, Donal; Chalandon, Yves; Kröger, Nicolaus.

In: HAEMATOLOGICA, Vol. 104, No. 9, 09.2019, p. 1782-1788.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Robin, M, de Wreede, LC, Wolschke, C, Schetelig, J, Eikema, D-J, Van Lint, MT, Knelange, NS, Beelen, D, Brecht, A, Niederwieser, D, Vitek, A, Bethge, W, Arnold, R, Finke, J, Volin, L, Yakoub-Agha, I, Nagler, A, Poiré, X, Einsele, H, Chevallier, P, Holler, E, Ljungman, P, Robinson, S, Radujkovic, A, McLornan, D, Chalandon, Y & Kröger, N 2019, 'Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis', HAEMATOLOGICA, vol. 104, no. 9, pp. 1782-1788. https://doi.org/10.3324/haematol.2018.205211

APA

Robin, M., de Wreede, L. C., Wolschke, C., Schetelig, J., Eikema, D-J., Van Lint, M. T., Knelange, N. S., Beelen, D., Brecht, A., Niederwieser, D., Vitek, A., Bethge, W., Arnold, R., Finke, J., Volin, L., Yakoub-Agha, I., Nagler, A., Poiré, X., Einsele, H., ... Kröger, N. (2019). Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis. HAEMATOLOGICA, 104(9), 1782-1788. https://doi.org/10.3324/haematol.2018.205211

Vancouver

Robin M, de Wreede LC, Wolschke C, Schetelig J, Eikema D-J, Van Lint MT et al. Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis. HAEMATOLOGICA. 2019 Sep;104(9):1782-1788. https://doi.org/10.3324/haematol.2018.205211

Bibtex

@article{a4180146c7654acf9453bea95c3d5a02,
title = "Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis",
abstract = "Allogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. Most post-transplantation events occur during the first two years and hence we aimed to analyze the outcome of 2-year disease-free survivors. A total of 1055 patients with myelofibrosis transplanted between 1995 and 2014 and registered in the registry of the European Society for Blood and Marrow Transplantation were included. Survival was compared to the matched general population to determine excess mortality and the risk factors that are associated. In the 2-year survivors, disease-free survival was 64% (60-68%) and overall survival was 74% (71-78%) at ten years; results were better in younger individuals and in women. Excess mortality was 14% (8-21%) in patients aged <45 years and 33% (13-53%) in patients aged ≥65 years. The main cause of death was relapse of the primary disease. Graft-versus-host disease (GvHD) before two years decreased the risk of relapse. Multivariable analysis of excess mortality showed that age, male sex recipient, secondary myelofibrosis and no GvHD disease prior to the 2-year landmark increased the risk of excess mortality. This is the largest study to date analyzing long-term outcome in patients with myelofibrosis undergoing transplant. Overall it shows a good survival in patients alive and in remission at two years. However, the occurrence of late complications, including late relapses, infectious complications and secondary malignancies, highlights the importance of screening and monitoring of long-term survivors.",
keywords = "Journal Article",
author = "Marie Robin and {de Wreede}, {Liesbeth C} and Christine Wolschke and Johannes Schetelig and Dirk-Jan Eikema and {Van Lint}, {Maria Teresa} and Knelange, {Nina Simone} and Dietrich Beelen and Arne Brecht and Dietger Niederwieser and Antonin Vitek and Wolfgang Bethge and Renate Arnold and J{\"u}rgen Finke and Liisa Volin and Ibrahim Yakoub-Agha and Arnon Nagler and Xavier Poir{\'e} and Hermann Einsele and Patrice Chevallier and Ernst Holler and Per Ljungman and Stephen Robinson and Aleksandar Radujkovic and Donal McLornan and Yves Chalandon and Nicolaus Kr{\"o}ger",
note = "Copyright {\textcopyright} 2019, Ferrata Storti Foundation.",
year = "2019",
month = sep,
doi = "10.3324/haematol.2018.205211",
language = "English",
volume = "104",
pages = "1782--1788",
journal = "HAEMATOLOGICA",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "9",

}

RIS

TY - JOUR

T1 - Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis

AU - Robin, Marie

AU - de Wreede, Liesbeth C

AU - Wolschke, Christine

AU - Schetelig, Johannes

AU - Eikema, Dirk-Jan

AU - Van Lint, Maria Teresa

AU - Knelange, Nina Simone

AU - Beelen, Dietrich

AU - Brecht, Arne

AU - Niederwieser, Dietger

AU - Vitek, Antonin

AU - Bethge, Wolfgang

AU - Arnold, Renate

AU - Finke, Jürgen

AU - Volin, Liisa

AU - Yakoub-Agha, Ibrahim

AU - Nagler, Arnon

AU - Poiré, Xavier

AU - Einsele, Hermann

AU - Chevallier, Patrice

AU - Holler, Ernst

AU - Ljungman, Per

AU - Robinson, Stephen

AU - Radujkovic, Aleksandar

AU - McLornan, Donal

AU - Chalandon, Yves

AU - Kröger, Nicolaus

N1 - Copyright © 2019, Ferrata Storti Foundation.

PY - 2019/9

Y1 - 2019/9

N2 - Allogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. Most post-transplantation events occur during the first two years and hence we aimed to analyze the outcome of 2-year disease-free survivors. A total of 1055 patients with myelofibrosis transplanted between 1995 and 2014 and registered in the registry of the European Society for Blood and Marrow Transplantation were included. Survival was compared to the matched general population to determine excess mortality and the risk factors that are associated. In the 2-year survivors, disease-free survival was 64% (60-68%) and overall survival was 74% (71-78%) at ten years; results were better in younger individuals and in women. Excess mortality was 14% (8-21%) in patients aged <45 years and 33% (13-53%) in patients aged ≥65 years. The main cause of death was relapse of the primary disease. Graft-versus-host disease (GvHD) before two years decreased the risk of relapse. Multivariable analysis of excess mortality showed that age, male sex recipient, secondary myelofibrosis and no GvHD disease prior to the 2-year landmark increased the risk of excess mortality. This is the largest study to date analyzing long-term outcome in patients with myelofibrosis undergoing transplant. Overall it shows a good survival in patients alive and in remission at two years. However, the occurrence of late complications, including late relapses, infectious complications and secondary malignancies, highlights the importance of screening and monitoring of long-term survivors.

AB - Allogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. Most post-transplantation events occur during the first two years and hence we aimed to analyze the outcome of 2-year disease-free survivors. A total of 1055 patients with myelofibrosis transplanted between 1995 and 2014 and registered in the registry of the European Society for Blood and Marrow Transplantation were included. Survival was compared to the matched general population to determine excess mortality and the risk factors that are associated. In the 2-year survivors, disease-free survival was 64% (60-68%) and overall survival was 74% (71-78%) at ten years; results were better in younger individuals and in women. Excess mortality was 14% (8-21%) in patients aged <45 years and 33% (13-53%) in patients aged ≥65 years. The main cause of death was relapse of the primary disease. Graft-versus-host disease (GvHD) before two years decreased the risk of relapse. Multivariable analysis of excess mortality showed that age, male sex recipient, secondary myelofibrosis and no GvHD disease prior to the 2-year landmark increased the risk of excess mortality. This is the largest study to date analyzing long-term outcome in patients with myelofibrosis undergoing transplant. Overall it shows a good survival in patients alive and in remission at two years. However, the occurrence of late complications, including late relapses, infectious complications and secondary malignancies, highlights the importance of screening and monitoring of long-term survivors.

KW - Journal Article

U2 - 10.3324/haematol.2018.205211

DO - 10.3324/haematol.2018.205211

M3 - SCORING: Journal article

C2 - 30733269

VL - 104

SP - 1782

EP - 1788

JO - HAEMATOLOGICA

JF - HAEMATOLOGICA

SN - 0390-6078

IS - 9

ER -